

TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYV
LIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLT
EILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGES
SEDCQSLTR (SEQ ID NO: 1)

TVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTF
ESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARV
(SEQ ID NO: 2)

CYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLE
EITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLAL
IHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLA (SEQ ID NO: 3)

CHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGS
VTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVD
LDDKGCPAEQRASPLT (SEQ ID NO: 4)

FIG. 1

Variable Light

```
                10        20          30          40
2C4       DTVMTQSHKIMSTSVGDRVSITC [KASQDVSIGVA] WYQQRP
           **    **** *      *                    *
574       DIQMTQSPSSLSASVGDRVTITC [KASQDVSIGVA] WYQQKP
                                   *   ** ***
hum κI    DIQMTQSPSSLSASVGDRVTITC [RASQSISNYLA] WYQQKP

                  50          60         0         80
2C4       GQSPKLLIY [SASYRYT] GVPDRFTGSGSGTDFTFTISSVQA
           **                  *  *          *    * *
574       GKAPKLLIY [SASYRYT] GVPSRFSGSGSGTDFTLTISSLQP
                     * *****
hum κI    GKAPKLLIY [AASSLES] GVPSRFSGSGSGTDFTLTISSLQP

                  90         100
2C4       EDLAVYYC [QQYYIYPYT] FGGGTKLEIK (SEQ ID NO:5)
            * *                 *   *
574       EDFATYYC [QQYYIYPYT] FGQGTKVEIK (SEQ ID NO:7)
                       *** *
hum κI    EDFATYYC [QQYNSLPWT] FGQGTKVEIK (SEQ ID NO:9)
```

FIG. 2A

Variable Heavy

```
                10        20          30          40
2C4       EVQLQQSGPELVKPGTSVKISCKAS [GFTFTDYTMD] WVKQS
              **  **  *  * ***  *                  * *
574       EVQLVESGGGLVQPGGSLRLSCAAS [GFTFTDYTMD] WVRQA
                                       ** * *
hum III   EVQLVESGGGLVQPGGSLRLSCAAS [GFTFSSYAMS] WVRQA

                  50  a      60          70         80
2C4       HGKSLEWIG [DVNPNSGGSIYNQRFKG] KASLTVDRSSRIVYM
          *  *   **                     *** *    **** *
574       PGKGLEWVA [DVNPNSGGSIYNQRFKG] RFTLSVDRSKNTLYL
                     ****** *** ****       * * *
hum III   PGKGLEWVA [VISGDGGSTYYADSVKG] RFTISRDNSKNTLYL

            abc       90          100ab         110
2C4       ELRSLTFEDTAVYYCAR [NLGPSFYFDY] WGQGTTLTVSS (SEQ ID NO:6)
          ***  **                              **
574       QMNSLRAEDTAVYYCAR [NLGPSFYFDY] WGQGTLVTVSS (SEQ ID NO:8)
                            ********
hum III   QMNSLRAEDTAVYYCAR [GRVGYSLYDY] WGQGTLVTVSS (SEQ ID NO:10)
```

FIG. 2B

Amino Acid Sequence for Pertuzumab Light Chain

```
1       10        20        30        40        50        60
|       |         |         |         |         |         |
DIQMTQSPSSLSASVGDRVTITC**KASQDVSIGVA**WYQQKPGKAPKLLIYS**ASYRYT**GVPS

        70        80        90        100       110       120
        |         |         |         |         |         |
RFSGSGSGTDFTLTISSLQPEDFATYYC**QQYYIYPYT**FGQGTKVEIKRTVAAPSVFIFPP

        130       140       150       160       170       180
        |         |         |         |         |         |
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT

        190       200       210
        |         |         |
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 11)
```

FIG. 3A

Amino Acid Sequence for Pertuzumab Heavy Chain

```
1       10        20        30        40        50        60
|       |         |         |         |         |         |
EVQLVESGGGLVQPGGSLRLSCAAS**GFTFTDYTMD**WVRQAPGKGLEWVA**DVNPNSGGSIY**

        70        80        90        100       110       120
        |         |         |         |         |         |
**NQRFK**GRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARN**LGPSFYFDY**WGQGTLVTVSSA

        130       140       150       160       170       180
        |         |         |         |         |         |
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG

        190       200       210       220       230       240
        |         |         |         |         |         |
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP

        250       260       270       280       290       300
        |         |         |         |         |         |*
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS

        310       320       330       340       350       360
        |         |         |         |         |         |
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM

        370       380       390       400       410       420
        |         |         |         |         |         |
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ

        430       440       448
        |         |         |
QGNVFSCSVMHEALHNHYTQKSLSLSPG  (SEQ ID NO: 12)
```

FIG. 3B

Trastuzmab Light Chain

```
1                         15                        30                        45
D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D V N T A V A W Y Q Q K P G K A P K

46                        60                        75                        90
L L I Y S A S F L Y S G V P S R F S G S R S G T D F T L T I S S L Q P E D F A T Y Y C Q Q

91                       105                       120                       135
H Y T T P P T F G Q G T K V E I K R T V A A P S V F I F P P S D E Q L K S G T A S V V C L

136                      150                       165                       180
L N N F Y P R E A K V Q W K V D N A L Q S G N S Q E S V T E Q D S K D S T Y S L S S T L T

181                      195                       210     214
L S K A D Y E K H K V Y A C E V T H Q G L S S P V T K S F N R G E C  (SEQ ID NO: 13)
```

FIG. 4A

Trastuzmab Heavy Chain

```
1                                 15                                30                                45
E V Q L V E S G G G L V Q P G G S L R L S C A A S G F N I K D T Y I H W V R Q A P G K G L

46                                60                                75                                90
E W V A R I Y P T N G Y T R Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D

91                               105                               120                               135
T A V Y Y C S R W G G D G F Y A M D Y W G Q G T L V T V S S A S T K G P S V F P L A P S S

136                              150                               165                               180
K S T S G G T A A L G C L V K D Y F P E P V T V S W N S G A L T S G V H T F P A V L Q S S

181                              195                               210                               225
G L Y S L S S V V T V P S S S L G T Q T Y I C N V N H K P S N T K V D K K V E P K S C D K

226                              240                               255                               270
T H T C P P C P A P E L L G G P S V F L F P P K P K D T L M I S R T P E V T C V V V D V S

271                              285                               300                               315
H E D P E V K F N W Y V D G V E V H N A K T K P R E E Q Y N S T Y R V V S V L T V L H Q D

316                              330                               345                               360
W L N G K E Y K C K V S N K A L P A P I E K T I S K A K G Q P R E P Q V Y T L P P S R E E

361                              375                               390                               405
M T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T T P P V L D S D G

406                              420                               435                              449
S F F L Y S K L T V D K S R W Q Q G N V F S C S V M H E A L H N H Y T Q K S L S L S P G
```

(SEQ ID NO: 14)

FIG. 4B

Pertuzumab Variant Light Chain

```
1                               15                              30                              45
V H S D I Q M T Q S P S S L S A S V G D R V T I T C K A S Q D V S I G V A W Y Q Q K P G K

46                              60                              75                              90
A P K L L I Y S A S Y R Y T G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y

91                              105                             120                             135
C Q Q Y Y I Y P Y T F G Q G T K V E I K R T V A A P S V F I F P P S D E Q L K S G T A S V

136                             150                             165                             180
V C L L N N F Y P R E A K V Q W K V D N A L Q S G N S Q E S V T E Q D S K D S T Y S L S S

181                             195                             210             217
T L T L S K A D Y E K H K V Y A C E V T H Q G L S S P V T K S F N R G E C  (SEQ ID NO: 15)
```

FIG. 5A

Pertuzumab Variant Heavy Chain

```
1                                 15                                30                                45
E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F T D Y T M D W V R Q A P G K G L

46                                60                                75                                90
E W V A D V N P N S G G S I Y N Q R F K G R F T L S V D R S K N T L Y L Q M N S L R A E D

91                                105                               120                               135
T A V Y Y C A R N L G P S F Y F D Y W G Q G T L V T V S S A S T K G P S V F P L A P S S K

136                               150                               165                               180
S T S G G T A A L G C L V K D Y F P E P V T V S W N S G A L T S G V H T F P A V L Q S S G

181                               195                               210                               225
L Y S L S S V V T V P S S S L G T Q T Y I C N V N H K P S N T K V D K K V E P K S C D K T

226                               240                               255                               270
H T C P P C P A P E L L G G P S V F L F P P K P K D T L M I S R T P E V T C V V V D V S H

271                               285                               300                               315
E D P E V K F N W Y V D G V E V H N A K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W

316                               330                               345                               360
L N G K E Y K C K V S N K A L P A P I E K T I S K A K G Q P R E P Q V Y T L P P S R E E M

361                               375                               390                               405
T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T T P P V L D S D G S

406                               420                               435                               449
F F L Y S K L T V D K S R W Q Q G N V F S C S V M H E A L H N H Y T Q K S L S L S P G K
```

(SEQ ID NO: 16)

FIG. 5B


Fab
Fab
Cys-23
Cys-88
VH
VL
CH1
CL
Papain Cleavage Site
CHO
CH2
CH3
Hinge
Fc

FIG. 6


Non-Reduced (Native) Tryptic Peptide Maps of Pertuzumab
mAU @ 214 nm
Minutes
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2

FIG. 7


Tryptic Peptide Maps of Reduced and Non-Reduced Pertuzumab (Full Scale)
Non-Reduced 2C4907-2
Reduced 2C4907-2
mAU @ 214 nm
Minutes
1,000
900
800
700
600
500
400
300
200
100
0
-100
-200
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
204

FIG. 8


Tryptic Peptide Maps of Reduced and Non-Reduced Pertuzumab (0-120 Minutes)
T35H=T40H
T21H=T27H
Non-Reduced 2C4907-2
Reduced 2C4907-2
mAU @ 214 nm
Minutes

FIG. 9


Tryptic Peptide Maps of Reduced and Non-Reduced Pertuzumab (120-204 Minutes)
mAU @ 214 nm
Minutes
T13H=T14H
T19H=T19H
T2L=T7L
T2H=T10H
T11L=T18L
Non-Reduced 2C4907-2
Reduced 2C4907-2

FIG. 10


HIC Analysis of Papain-Digested Pertuzumab
Fc
Fab
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank
mAU @ 280 nm
275
200
150
100
50
-10
0.8
2.5
3.8
5.0
6.3
7.5
8.8
10.0
11.3
12.5
13.8
15.0
16.3
17.5
18.8
20.0
21.0
Minutes

FIG. 11


HIC Analysis of Papain-Digested Pertuzumab (Expanded View)
mAU @ 280 nm
Minutes
60.0
50.0
40.0
30.0
20.0
10.0
-3.0
5.0
6.0
7.0
8.0
9.0
10.0
11.0
12.0
13.0
14.0
15.0
16.0
17.0
Fab
Free Thiol-Fab
Fc
Fc Oxidation
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank

FIG. 12


HIC Analysis of Intact Pertuzumab
mAU @ 280 nm
Minutes
Wild-Type Homodimer
Free Thiol Heterodimer
Enriched Free Thiol Homodimer
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank

FIG. 13


Activity of Pertuzumab (Batch anti2C4907-2) in the ADCC Assay
HER2 3+
HER2 3+
HER2 1+
% Cytotoxicity
Concentration (ng/mL)
120
110
100
90
80
70
60
50
40
30
20
10
0
1
10
100
1000
10000

FIG. 14


Impact of G0-F Level on ADCC Activity
Pertuzumab Phase III Reference Standard Batch anti2C4907-2; G0-F=2.2%
Pertuzumab Phase I Reference Standard Batch anti2C4907-1; G0-F=0.8%
% Cytotoxicity
Concentration (ng/mL)
110
100
90
80
70
60
50
40
30
20
10
0
-10
1
10
100
1000
10000

FIG. 15


Capillary Electrophoresis Analysis of N-Linked Oligosaccharides Released from Pertuzumab
RFU
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4907-2
2C4900-1
Blank
9.0 9.2 9.4 9.6 9.8 10.0 10.2 10.4 10.6 10.8 11.0 11.2 11.4 11.6 11.8 12.0 12.2 12.4 12.6 12.8 13.0
Minutes

FIG. 16


Capillary Electrophoresis Analysis of N-Linked Oligosaccharides Released from Pertuzumab (Expanded View)
G2+NANA
G0-F
G0-GlcNAc
Man 5
G0
G1-GlcNAc
G1'-GlcNAc
Peak A
G1
G1'
G2
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4907-2
2C4900-1
Blank
RFU
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
9.0 9.2 9.4 9.6 9.8 10.0 10.2 10.4 10.6 10.8 11.0 11.2 11.4 11.6 11.8 12.0 12.2 12.4 12.6 12.8 13.0
Minutes

FIG. 17


UV (280 nm)
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
-5.0
3.0
5.0
6.3
7.5
8.8
10.0
11.3
12.5
13.8
15.0
16.3
17.5
19.0
Time (Min)
Fc
Fab
NEM Tagged Pertuzumab Domain RP-HPLC
Pertuzumab Domain RP-HPLC
Free Thiol Fab

FIG. 18


RT: 9.28 - 38.18
L2
19.51
21.01
L2+NEM
31.21
31.16
Fab
Pre-Fab
19.50
24.89
31.98
33.97
Relative Abundance
Relative Abundance
Time (Min)

FIG. 19



FIG. 20A



FIG. 20C


Fab
Fab
Fab
Fab
VH
VL
CH1
CL
Papain Cleavage Site
CHO
CH2
CH3
Hinge
Fc

FIG. 20B


G0-F Versus ADCC Activity for Pertuzumab Batches
y = 30.133x + 12.439
R2 = 0.8555
ADCC Activity
G0-F (% CPA)
0
20
40
60
80
100
120
140
160
180
0.00
1.00
2.00
3.00
4.00
5.00

FIG. 21



FIG. 22

Trastuzumab
HERCEPTIN



- Binds in Subdomain IV.
- Protects against receptor shedding
- Moderately affects receptor down-modulation
- Slight effect on HER2's role as a coreceptor

Pertuzumab
PERJETA



- Binds in Subdomain II at dimerization interface
- Does not prevent receptor shedding
- Moderately affects receptor down-modulation
- Major effect on HER2's role as a coreceptor

FIG. 23

FIG. 24A

Oligosaccharide Structures attached to IgG1

Structures	Abbreviation	Mass
Manα(1–>6) Manα(1–>3) > Manα(1–>6) Manα(1–>3) > Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc-	Man5	1235
GlcNAcβ(1–>2) { Manα(1–>6) Manα(1–>3) > Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc- (Fucα(1–>6) on GlcNAc)	G-1	1260
GlcNAcβ(1–>2)Manα(1–>6) GlcNAcβ(1–>2)Manα(1–>3) > Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc-	G0-F	1317
Manα(1–>6) Manα(1–>3) > Manα(1–>6) Manα(1–>2)Manα(1–>3) > Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc-	Man6	1398

Oligosaccharide Structures attached to IgG1

Structures	Abbreviation	Mass
Galβ(1–>4)GlcNAcβ(1–>2){Manα(1–>6), Manα(1–>3)}> Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc- (Fucα(1–>6) on GlcNAc)	G1-1	1423
GlcNAcβ(1–>2)Manα(1–>6), GlcNAcβ(1–>2)Manα(1–>3)> Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc- (Fucα(1–>6) on GlcNAc)	G0	1463
Galβ(1–>4)GlcNAcβ(1–>2)Manα(1–>6), GlcNAcβ(1–>2)Manα(1–>3)> Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc- (Fucα(1–>6) on GlcNAc)	G1 (1-6)	1626
GlcNAcβ(1–>2)Manα(1–>6), Galβ(1–>4)GlcNAcβ(1–>2)Manα(1–>3)> Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc- (Fucα(1–>6) on GlcNAc)	G1 (1-3)	1626
Galβ(1–>4)GlcNAcβ(1–>2)Manα(1–>6), Galβ(1–>4)GlcNAcβ(1–>2)Manα(1–>3)> Manβ(1–>4)GlcNAcβ(1–>4)GlcNAc- (Fucα(1–>6) on GlcNAc)	G2	1788

Masses shown in this figure correspond to the $(M+Na)^+$ values.

FIG. 24B


Size-Exclusion Chromatography Analysis of Pertuzumab (Full Scale)
mAU @ 280 nm
Minutes
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank
2,000
1,875
1,750
1,625
1,500
1,375
1,250
1,125
1,000
875
750
625
500
375
250
125
0
-125
-200
0.0 1.3 2.5 3.8 5.0 6.3 7.5 8.8 10.0 11.3 12.5 13.8 15.0 16.3 17.5 18.8 20.0 21.3 22.5 23.8 25.0 26.3 27.5 28.8 30.0

FIG. 25


Size-Exclusion Chromatography Analysis of Pertuzumab (Expanded Scale)
mAU @ 280 nm
Minutes
HMWS
Main Peak
LMWS
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank
10.7
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
-1.5
9.4
10.0
11.0
12.0
13.0
14.0
15.0
16.0
17.0
18.0
19.0
20.0
21.0
22.0
23.0

FIG. 26


SE-HPLC Analysis of Pertuzumab Samples with Increased HMWS
mAU @ 280 nm
400
300
200
100
0
-100
8
10
12
14
16
18
20
23
Minutes
HMWS
LMWS
Main Peak
Sample E
Sample D
Sample C
Sample B
Sample A

FIG. 27


Concordance Plot of AUC Sedimentation Velocity and SE-HPLC Analysis
% HMWS by SE-HPLC
% HMWS by Sedimentation Velocity
A
B
C
D
E
0
1
2
3
4
5
6
7
8
9

FIG. 28


Capillary Electrophoresis Sodium Dodecyl Sulfate Analysis with
Laser-Induced Fluorescence Detection of Non-Reduced Pertuzumab
RFU
Minutes
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank

FIG. 29


Capillary Electrophoresis Sodium Dodecyl Sulfate Analysis with Laser-Induced Fluorescence Detection of Non-Reduced Pertuzumab (Expanded View)
RFU
Minutes
Main
HMWS
Peak 1
Peak 2
Peak 3
Peak 4
Peak 5
Peak 6
Run 7
Run 6
Run 5
Run 4
Run 3
Run 1
2C4900-1
2C4907-2
Blank

FIG. 30


SE-HPLC Chromatograms (Full Scale)
Main Peak
DP Stability
Accelerated Stability
Thermal
Acid Treated
2C4907-2
Blank
mAU @ 280 nm
Minutes
1,600
1,500
1,400
1,300
1,200
1,100
1,000
900
800
700
600
500
400
300
200
100
0
-100
-200
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
22.0
24.0
26.0
28.0
30.0

FIG. 31A


SE-HPLC Chromatograms (Expanded Scale)
mAU @ 280 nm
Minutes
HMWS
LMWS
DP Stability
Accelerated Stability
Thermal
Acid Treated
2C4907-2
Blank
250
220
200
180
160
140
120
100
80
60
40
20
0
-25
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
22.0
24.0
26.0
28.0
30.0

FIG. 31B


Non-Reduced CE-SDS Electropherograms (Full Scale)
RFU
Minutes
DP Stability
Accelerated Stability
Thermal
Acid Treated
2C4907-2
Blank

FIG. 32A


Non-Reduced CE-SDS Electropherograms (Expanded Scale)
HMWS
DP Stability
Accelerated Stability
Thermal
Acid Treated
2C4907-2
Blank
1
2
2a
3
4
5
6
RFU
Minutes

FIG. 32B


Reduced CE-SDS Electropherograms (Full Scale)
HC
LC
DP Stability
Accelerated Stability
Thermal
Acid Treated
2C4907-2
Blank
RFU
Minutes
0
2
4
6
8
10
12
14
16
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38

FIG. 33A


Reduced CE-SDS Electropherograms (Expanded Scale)
Incomplete Reduction
DP Stability
Accelerated Stability
Thermal
Acid Treated
2C4907-2
Blank
NGHC
1
2
3
5
RFU
Minutes

FIG. 33B


Comparison of Non-Reduced and Reduced CE-SDS Electropherograms
for the Acid Treated Sample (Expanded Scale)
RFU
Minutes
Reduced
Non-Reduced
1
2
NGHC
3
1
2
2a
3
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40

FIG. 34


Correlation of Fab Quantitation between Non-Reduced CE-SDS and SE-HPLC
y = 1.1597x - 0.0806
R2 = 0.9704
LMWS by SE-HPLC
Peak 3 (Fab) by NR CE-SDS
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7

FIG. 35